NCT01657760View on ClinicalTrials.gov

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 1, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

September 1, 2017

Conditions
Alcohol Dependence
Interventions
DRUG

citalopram

citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.

Trial Locations (1)

90073

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT01657760 - Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics | Biotech Hunter | Biotech Hunter